Articles with public access mandates - Marwan FakihLearn more
Not available anywhere: 7
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
MW Saif, CR Becerra, MG Fakih, W Sun, L Popovic, S Krishnamurthi, ...
Cancer Chemotherapy and Pharmacology 88 (3), 485-497, 2021
Mandates: US National Institutes of Health
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ...
The Lancet Oncology 22 (6), 779-789, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity
J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ...
Nature 575 (7781), 217-223, 2019
Mandates: US Department of Energy, US National Institutes of Health, Howard Hughes …
Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
K Raghav, JM Loree, JS Morris, MJ Overman, R Yu, F Meric-Bernstam, ...
JCO Precision Oncology 3, 1-13, 2019
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Phase Ib trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma
V Chung, P Frankel, D Lim, C Yeon, L Leong, J Chao, N Ruel, ...
Oncology 90 (6), 307-312, 2016
Mandates: US National Institutes of Health
Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N 1, N 11 diethylnorspermine
S Hector, R Tummala, ND Kisiel, P Diegelman, S Vujcic, K Clark, M Fakih, ...
Cancer chemotherapy and pharmacology 62, 517-527, 2008
Mandates: US National Institutes of Health
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors
MG Fakih, L Pendyala, W Brady, PF Smith, ME Ross, PJ Creaven, ...
Cancer chemotherapy and pharmacology 62, 499-508, 2008
Mandates: US National Institutes of Health
Available somewhere: 65
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
A Mohanty, A Nam, S Srivastava, J Jones, B Lomenick, SS Singhal, L Guo, ...
Science Advances 9 (41), eade3816, 2023
Mandates: Department of Biotechnology, India, Department of Science & Technology, India
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
JJ Luke, M Fakih, C Schneider, EG Chiorean, J Bendell, R Kristeleit, ...
British journal of cancer 128 (12), 2227-2235, 2023
Mandates: Banking Foundation "la Caixa", Government of Spain
P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or …
V Morris, K Guthrie, S Kopetz, R Breakstone, T Karasic, Z Hu, S Colby, ...
Annals of Oncology 34, S96, 2023
Mandates: US National Institutes of Health
Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized …
M Fakih, J Sandhu, D Lim, X Li, S Li, C Wang
JAMA oncology 9 (5), 627-634, 2023
Mandates: US National Institutes of Health
Treatment of metastatic colorectal cancer: ASCO guideline
VK Morris, EB Kennedy, NN Baxter, AB Benson III, A Cercek, M Cho, ...
Journal of Clinical Oncology 41 (3), 678-700, 2023
Mandates: US National Institutes of Health, A*Star, Singapore
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical …
M Fakih, W Harb, D Mahadevan, H Babiker, J Berlin, T Lillie, D Krige, ...
Journal for Immunotherapy of Cancer 11 (4), 2023
Mandates: US National Institutes of Health
Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and …
M Raoof, KM Sullivan, PH Frankel, M Fakih, TW Synold, D Lim, Y Woo, ...
Pleura and Peritoneum 7 (4), 169-177, 2022
Mandates: US National Institutes of Health
315O sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase ib full expansion cohort
Y Kuboki, R Yaeger, MG Fakih, JH Strickler, T Masuishi, EJ Kim, ...
Annals of Oncology 33, S680-S681, 2022
Mandates: US National Institutes of Health
Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection
AM D’Alise, N Brasu, C De Intinis, G Leoni, V Russo, F Langone, D Baev, ...
Science translational medicine 14 (657), eabo7604, 2022
Mandates: US National Institutes of Health, AIRC Foundation for Cancer Research in Italy
Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer
C Li, A Ferro, SK Mhatre, D Lu, M Lawrance, X Li, S Li, S Allen, J Desai, ...
Communications Medicine 2 (1), 90, 2022
Mandates: US National Institutes of Health
Cancer survivors, oncology, and primary care perspectives on survivorship care: an integrative review
M Love, M Debay, AC Hudley, T Sorsby, L Lucero, S Miller, S Sampath, ...
Journal of Primary Care & Community Health 13, 21501319221105248, 2022
Mandates: US National Institutes of Health
Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy
X Cao, J Chen, B Li, J Dang, W Zhang, X Zhong, C Wang, M Raoof, Z Sun, ...
Science Advances 8 (11), eabl9171, 2022
Mandates: US National Institutes of Health, Lymphoma Research Foundation, USA, V …
A phase 2 trial combining pembrolizumab and palliative radiation therapy in gastroesophageal cancer to augment abscopal immune responses
J Chao, TF He, M D'Apuzzo, YJ Chen, P Frankel, M Tajon, H Chen, ...
Advances in Radiation Oncology 7 (1), 100807, 2022
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program